Performance of the BD MAX[™] CT/GC/TV for Detection of Chlamydia, Gonorrhoea and Trichomonas

> Barbara Van Der Pol, PhD, MPH University of Alabama at Birmingham

Disclosures

- Atlas Genetics
- BD Diagnostics [provided funding for this study]
- Beckman Coulter
- Cepheid
- Rheonix
- Roche Molecular

Background

- Most recent WHO estimates of incident STI
 - Chlamydia 105.7 million 4.1% ↑
 - Gonorrhea 106.1 million 21.0% ↑
 - Trichomonas 276.4 million 11.2% ↑
- Platforms suitable to smaller volume labs are needed to keep testing "local"
 - Some level of automation is desirable

BD MAX[™] System

- Small platform
- <u><</u> 24 samples/controls per run
- < 15 min/run hands-on time</p>
- ~ 4 hours per run
- BD MAXTM Enteric Bacterial Panel
 BD MAXTM Enteric Parasite Panel
 BD MAXTM Enteric Parasite Panel

_

BD MAXTM CT/GC

– BD MAX[™] StaphSR

– BD MAX[™] CDiff

BD MAX[™] GBS

Broad menu − BD MAXTM MRSA XT

- BD MAX[™] CT/GC/TV
- BD MAX[™] GC rtPCR
- Partner menu:
 - Diagenode[™] Enteric Viral Panel
 Diagenode[™] Respiratory FLU A/B

Study Design – Patient Samples

- 8 US Recruitment sites, 4 US BD MAX[™] System testing sites
- Women
 - Urine
 - 1 self-obtained vaginal swab (SOV)
 - 2 clinician-obtained vaginal swabs (COV)
 3 endocervical swabs (EC)
- Men
 - Urethral swab
 - Urine

Study Design – Women



Vaginal swab	127/1746 (7.2%)	99.2% (95.7-99.9%)	98.6% (98.0-99.1%)
Endocervical swab	124/1740 (7.1%)	96.8% (92.0-98.7%)	99.3% (98.7-99.6%)
Female Urine	128/1758 (7.3%)	92.2% (86.2-95.7%)	99.5% (99.0-99.8%)
Male Urine	177/803 (22.0%)	96.6% (92.8-98.4%)	99.5% (98.6-99.8%)

*Total PIS +/Total enrolled



Specificity

Results – Trichomonas

Specimen Type	(+)/n·	Sensitivity (95% Cl)	Specificity (95% CI)
Vaginal swab	152/1048 (14.5%)	96.1% (91.7-98.2%)	98.9% (98.0-99.4%)
Endocervical swab	152/1039 (14.6%)	93.4% (88.3-96.4%)	99.3% (98.5-99.7%)
Female Urine	154/1047(14.7%)	92.9% (87.7-96.0%)	99.3% (98.5-99.7%)

*Total PIS +/Total enrolled

Summary

- Rates of treatable STI remain high
 - CT: 7% in women, 22% in men
 - GC: 2% in women, 13% in men
 - TV: 14% in women
 - The BD MAX[™] CT/GC/TV assay is the first true multiplexed commercial assay for all 3 organisms
- Sensitivity & specificity was high for all organism across all specimen types
- The BD MAX CT/GC/TV assay *performed well* in the presence of *mixed infections*

SCHOOL OF MEDICINE

Study Design – Men



Results – Gonorrhea

Specimen Type	(+)/n·	Sensitivity (95% Cl)	Specificity (95% CI)
Vaginal swab	39/1746 (2.2%)	94.9% (83.1-98.6%)	99.8% (99.5-99.9%)
Endocervical swab	39/1733 (2.3%)	94.9% (83.1-98.6%)	99.9% (99.7-100%)
Female Urine	41/1758 (2.3%)	95.1% (83.9-98.7%)	99.7% (99.3-99.9%)
Male Urine	107/812 (13.2%)	99.1% (94.9-99.8%)	100% (99.5-100%)

*Total PIS +/Total enrolled

Results – Mixed Infections

Specimen Type	CT	GC	TV
	(+)/n	(+)/n	(+)/n
	Sensitivity	Sensitivity	Sensitivity
Vaginal swab	25/26	15/16	18/18
	96.2%	93.8%	100%
Endocervical	25/26	16/16	17/18
swab	96.2%	100%	94.4%
Female Urine	25/27	17/18	17/19
	92.6%	94.4%	89.5%
Male Urine	30/33 90.9%	33/34 97.1%	

Application

- Combined TV with CT/GC is useful in many settings and may provide time/cost savings
- Testing locally may also save time and reduce costs and is therefore desirable in some settings
 - A platform designed for smaller volume labs, with a broad menu, can facilitate this

My collaborators

Tom Davis

- James WilliamsDeAnna Fuller
- s Indiana University Eskenazi Health Services
 - Eskenazi Health Services

Louisiana State University

- Grace Daniel
 University of Alabama at Birmingham
- Ned Hook University of Alabama at Birmingham
- Stephanie Taylor

THANKS FOR YOUR ATTENTION